Research suggests that intranasal nanosuspensions offer a promising way to formulate and deliver drugs that are poorly soluble in water to patients with chronic conditions.
Rajesh Patil, PhD
Advertisement
Rajesh Patil, PhD, is currently pharmaceutical development leader at Elanco, formerly a division of Eli Lilly & Company, IN.
Articles by Rajesh Patil, PhD
Advertisement
Latest Updated Articles
Assessment of Nanosuspension Formulation for Intranasal AdministrationSeptember 2nd 2020
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
2
Why Impurity Deficiencies Keep Repeating: AAPS PharmSci 360 2026
3
Expert Commentary on Formulation, Scale-Up, and Patient-Centered Design Found at CPHI Milan
4
AAPS PharmSci 360: How USP Is Tackling the Novel Excipient Roadblock
5